Laboratoires Théa acquires The EyeBag brand
The company will add the MGDRx EyeBag to its dry eye portfolio
Pharmaceutical company, Laboratoires Théa, has acquired The EyeBag brand, introducing it to its dry eye portfolio.
Founded in 2004 by consultant ophthalmologist, Professor Teifi James, The EyeBag offers a patented reusable warm compress, the MGDRx EyeBag. The compress provides a treatment for dry eye, meibomian gland dysfunction (MGD), blepharitis and associated symptoms.
The product has been widely adopted in the UK by eye care professionals.
Calling the acquisition “an exciting addition to the Théa portfolio,” Philip Lewis Williams, managing director of Théa UK, commented: “We have worked closely with Professor James for a number of years, starting with the development of the Théa Dry Eye Project.”
“The MGDRx EyeBag is the missing piece in Théa’s dry eye and MGD portfolio. We are delighted that we can now offer a full range of products to patients and practitioners alike looking for a complete treatment of their dry eye,” he added.
With Théa’s research and development experience and distribution network of more than 70 countries, the company suggested its platform would be “ideal” to introduce The EyeBag to a global audience.
James, managing director of The EyeBag Co, commented: “We are taking this new and exciting direction with Théa which will be good for our customers, our people, and the eye care sector.”
The companies have confirmed that whilst distribution transitions to the Théa network, the product will continue to be available through practitioner’s usual distributors or through the EyeBag sales team.